About Monoclonal Antibodies in COVID Prevention:

How it works–Participants must be over 18 and there is no upper limit to participate. This is not a vaccine. Instead, the antibodies attack the COVID-19 virus directly, binding to the COVID-19 “spike” protein. This protein is a protein on coronavirus that is essential to replication of the virus. When it is blocked, the virus cannot infect the cells of your body. If the virus does not enter your cells, it cannot replicate and dies off without causing an infection. 
What is my chance of getting the antibody?  2 out of 3. Of the participants, 67 percent will get the antibody in the form of a shot, and 33 percent of participants will receive the placebo, which does not include the antibody.
Is this a late stage trial? Yes. AstraZeneca’s long-acting antibody combination will advance into late stage Phase III clinical trials with approximately 5,000 participants in and outside the U.S. The trial will evaluate the safety and efficacy of these antibodies to prevent infection for up to 12 months.
How do I get more information? If you are interested and would like more information, please fill out the contact form on this page. Filling out the form does not commit you to the study, but you will be contacted to provide more information and to answer additional questions.
Study-related care is available to participants at no cost and health insurance is not required, nor needed. Participants will be compensated, up to $875 for time and travel, if they qualify and enroll in the study.
Thanks again for all you are doing as we fight this pandemic together!

Baptist Health Center for Clinical Research:

We offer two clinical studies that may prevent COVID infection in you or those around you if you are already COVID positive:

  • Storm Chaser: Antibodies (not a vaccine) that may prevent COVID infection in people who live with a person recently diagnosed with Covid 19.

A study to look at the effectiveness of monoclonal antibodies in preventing Covid-19 in people living with a COVID positive person.  If you are interested in learning more about the study, please have the exposed person fill out the contact form within a few days after the COVID positive person tests positive.  For example, Margaret Jones test positive for Covid on January 25. Those living with her who are interested in the study need to fill out the contact form by January 27 or 28th.  Please fill out a contact form on this page we will contact you.

  • Provent: Antibodies (not a vaccine) that may prevent Covid infection in people who do not want to, do not have access to or cannot take a Covid vaccine.

A study to look at the effectiveness of monoclonal antibodies preventing Covid 19 in people who have not taken the Covid vaccine.  If you do not want to, do not have access to or cannot take a Covid vaccine, please fill out a contact form on this page and we will contact you.

These studies are enrolling now and filling up fast!

Go to “Do you qualify?” on this page and Check now.

Current status of COVID-19 vaccines - 02/01/2021

Currently, there is no FDA-approved vaccine to prevent COVID-19.  On December 12, 2020 the FDA  authorized the emergency use of the Pfizer-BioNTech COVID-19 Vaccine to prevent COVID-19 in individuals 16 years of age and older under an Emergency Use Authorization (EUA). The Pfizer-BioNTech COVID-19 Vaccine is the first  unapproved vaccine to receive an emergency authorization. On December 19, the FDA authorized the emergency use of Modurna’s Covid–19 vaccine. Other unapproved vaccines may be authorized for emergency use soon.
 
Clinical studies continue with the Pfizer, Moderna and other vaccines and long-term safety and efficacy data will be collected over the next 2 years. According to Dr. Fauci, an authorized vaccine will not be available to the general public until late March or April of 2021, although distribution to certain high risk populations will start sooner. 
 
If you are involved in a research study and a vaccine is authorized for emergency use, it is likely most studies will allow you to take the authorized vaccination and continue in the study, although this is yet to be determined.  Even after this, participants will be asked to stay in the study so that they can be monitored closely for long term safety concerns, if any.

Qualifications

  • 18+ years old
  • Please note, other conditions may apply.